The Securities and Exchange Commission (SEC) has reportedly launched an investigation into Cassava Sciences in response to allegations made against the clinical-stage biopharmaceutical company by a law firm representing anonymous short sellers.

Learn More
Already a member? Sign in to an existing account.

Jaclyn Jaeger is a freelance contributor to Compliance Week after working for the company for 15 years. She writes on a wide variety of topics, including ethics and compliance, risk management, legal,...